X
<

Bristol-Myers Squibb’s Latest Developments and Valuation

PART:
1 2 3 4 5 6 7 8
Part 3
Bristol-Myers Squibb’s Latest Developments and Valuation PART 3 OF 8

Analyzing Bristol-Myers Squibb’s Oncology Portfolio

Oncology portfolio

Bristol-Myers Squibb’s (BMY) oncology portfolio includes its Empliciti, Opdivo, Sprycel, and Yervoy products.

Analyzing Bristol-Myers Squibb’s Oncology Portfolio

Interested in BIIB? Don't miss the next report.

Receive e-mail alerts for new research on BIIB

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The chart above shows revenues for the company’s oncology products over the last few quarters.

Empliciti

Empliciti is a new drug approved for use in combination with Celgene’s (CELG) Revlimid and dexamethasone in previously treated patients with multiple myeloma. It reported 62% growth in revenues to $55 million in 2Q17, compared to $34 million in 2Q16.

Opdivo

Opdivo is a human PD-1 blocking antibody approved for the treatment of various forms of cancer. It reported 42% growth in revenues to $1.19 billion in 2Q17, compared to revenues of $840 million in 2Q16. We discuss Opdivo’s performance and recent developments later in this series!

Sprycel

Sprycel is an oral inhibitor used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia as well as Philadelphia chromosome-positive acute lymphoblastic leukemiar. It reported 12% growth in revenues to $506 million in 2Q17, compared to $451 million in 2Q16. The growth was driven by increased demand for the drug in US markets.

Yervoy

Yervoy, a monoclonal antibody, is approved for the treatment of certain types of melanoma. Yervoy reported 34% growth in revenues to $322 million in 2Q17, compared to $241 million in 2Q16. The growth was driven by an increase in sales in US markets, offset by weaker sales across international markets due to competition.

To divest company-specific risks, investors can consider ETFs like the Fidelity MSCI Health Care ETF (FHLC), which invests 2.8% of its total assets in Bristol-Myers Squibb (BMY). FHLC also invests 9.7% in Johnson & Johnson (JNJ), 3.0% in Medtronic (MDT), and 1.9% in Biogen (BIIB).

X

Please select a profession that best describes you: